LONDON, June 21, 2023 -- MediSieve, a leading innovator in the biotech industry, proudly announced today that it has secured second place in the Biotech category of the prestigious EIT Health Catapult. The event, held at the esteemed Bits & Pretzels conference in Munich, aims to accelerate the growth of European health start-ups by providing them with invaluable access to industry experts and potential investors.

The EIT Health Catapult, delivered by EIT Health and run by three esteemed partners - Cap Digital, Medical Valley, and BioRN, has a proven track record of empowering European health start-ups and bringing fresh perspectives to the industry. Throughout the program, participating start-ups receive intensive training, fostering their credibility and visibility through extensive pan-European exposure. The winners of the EIT Health Catapult also receive prizes from prominent industry sponsors: Amazon Web Services (AWS), Astrazeneca, eg technology, Lusiadas, McDermott Will & Emery and Merck.

MediSieve's outstanding performance in the competition not only earned them the highly coveted second-place position in the Biotech category but also secured them the prestigious Industry Prize, accompanied by a monetary reward of €20,000. This recognition further solidifies MediSieve's position as a trailblazer in the field, showcasing its dedication to revolutionising healthcare through its innovative technologies.

George Frodsham, CEO of MediSieve, expressed his gratitude and excitement, stating, "We are honored to have received second place in the EIT Health Catapult and to be recognised among Europe's most inspiring start-ups. This achievement reflects the hard work and dedication of the entire MediSieve team. We are committed to transforming healthcare by advancing our groundbreaking solutions, and this recognition will undoubtedly propel us towards our mission."

Magda Krakowiak, Director of Business Creation, EIT Health, shared her excitement: “Each year, the EIT Health Catapult unearths some of Europe’s most inspiring start-ups, and the 2023 competition was no exception. The reveal of the winners at yesterday’s finals at the Bits & Pretzels Conference marked another milestone in European healthcare innovation. We stand ready to support these start-ups in their mission to transform healthcare.”

MediSieve's impressive achievement at the EIT Health Catapult not only validates their pioneering work but also positions them for future success as they continue to push the boundaries of biotechnology and healthcare innovation. With the generous support of EIT Health and the recognition garnered from this prestigious event, MediSieve is poised to make an even greater impact in revolutionising healthcare for the better.

About Magnetic Blood Filtration 

MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.

About MediSieve

MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.

MEDIA CONTACT:

Alina Kagermazova

alina@medisieve.co.uk

INVESTOR AND PARTNERSHIP CONTACT:

George Frodsham

george@medisieve.co.uk